UBS’s bluebird bio BLUE Stock Holding History

UBS’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$11K	Buy	+23	New	+$10.6K	﹤0.01%	8695

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TRV

Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS's BLUE Position: Q3 2014 in Review

UBS reduced its bluebird bio (BLUE) stake by 70% in Q3 2014, selling an estimated $50.3K and leaving 46 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #7872.

UBS first reported a position in BLUE in Q3 2013 and has held it in 5 quarters since. The position peaked at $77K in Q2 2014. 123 funds tracked by Wall St. Rank hold BLUE as of Q3 2014.

UBS held 46 shares of bluebird bio worth $22K as of Q3 2014.
UBS sold 109 bluebird bio shares in Q3 2014, an estimated $50.3K.
bluebird bio made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7872 holding.
UBS first reported a position in bluebird bio in Q3 2013 and has held it in 5 quarters since.
UBS's bluebird bio position peaked at $77K in Q2 2014.
123 funds tracked by Wall St. Rank held bluebird bio as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.